Clinical trial · Observational
Anlotinib Retrospective Study for Esophageal Cancer
Efficacy and Safety of Anlotinib in the First-line or Second-line Treatment of Locally Advanced or Metastatic Esophageal Cancer in China, a Retrospective, Multicenter, Real-world Study
NCT05303740CI-TRIAL-00057408completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. The purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and second line of advanced esophageal cancer in the real world.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Neoplasms | Esophageal Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anlotinib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Anlotinib
- interventionNames
- Drug: Anlotinib
Primary outcomes (1)
- measure
- PFS
- timeFrame
- From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
- description
- Progression Free Survival
Secondary outcomes (1)
- measure
- OS
- timeFrame
- From date of admission until the date of death from any cause, assessed up to 24 months
- description
- Overall Survival
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Esophageal cancer diagnosed pathologically or clinically * Patients who use anlotinib alone, or combined with chemoradiotherapy, or plus PD-1 inhibitors in first-line or second-line treatment Exclusion Criteria: None
References
Publications (0)
Data not yet available
No reference posted for this study.